A. Swaisland

发表

Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study.

T. Hickish, D. Cunningham, I. Chau, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?

B. Davies, R. Wilkinson, G. Speake, 2009, Anti-cancer drugs.

The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib

A. Harris, J. Carmichael, C. Twelves, 2011, Cancer Chemotherapy and Pharmacology.

Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers.

N. Rizzo-Padoin, C. Verstuyft, L. Becquemont, 2009, British journal of clinical pharmacology.

Geﬁtinib–phenytoin interaction is not correlated with the 14 C-erythromycin breath test in healthy male volunteers

N. Rizzo-Padoin, C. Verstuyft, L. Becquemont, 2009 .

Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors

J. Baselga, I. Chirivella, J. Tabernero, 2010, Clinical Cancer Research.

I. Chirivella, J. Tabernero, P. Elvin, 2010 .

Effects of the Src inhibitor saracatinib (AZD0530) on renal function in healthy subjects.

R. Dalton, A. Swaisland, M. Stuart, 2010, Anticancer research.

Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma

R. McLendon, A. Friedman, D. Bigner, 2006, Clinical Cancer Research.

Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study

M. Gross, D. Agus, L. Leichman, 2011, Cancer Chemotherapy and Pharmacology.

Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose phase I trial

Richard Eastell, R. Eastell, G. Clack, 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

F. Hirsch, A. Armour, M. Varella‐Garcia, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I, open-label, multicenter study of cediranib and AZD0530 in patients with advanced solid tumors

T. Gauler, J. Drevs, T. Trarbach, 2008 .

Clinical Cancer esearch cer Therapy : Clinical se I Safety , Pharmacokinetics , and Inhibition of Src R ivity Study of Saracatinib in Patients with Solid Tumors

I. Chirivella, J. Tabernero, P. Elvin, 2010 .

Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors

I. Chirivella, E. Casado, A. Swaisland, 2010 .